Caremo R&D Headquarters Officially Breaks Ground!

· Get ready for a new journey

December 30, 10:00 AM – The groundbreaking ceremony for Caremo’s R&D Headquarters was successfully held in Nanjing. Located north of Weidi Road in Qixia District (Plot EAc030-02-09), the headquarters is nestled among Nanjing’s iconic landscapes: flanked by the Purple Mountain to the west, Qixia Mountain to the north, Baohua Mountain to the east, and Qinglong Mountain to the south. Upon completion, the facility will span over 35,000 sqm and is expected to be operational by June 2025.

· A new chapter of Caremo

The construction of the R&D Headquarters marks a milestone in Caremo’s development, propelling the company into a new phase of growth.

Caremo remains steadfast in its mission—“Born for Health, Empowered for Innovation”—by advancing open innovation platforms and integrating core technologies across the “innovative + generic drug” lifecycle. Through a dual-drive strategy of R&D and industrialization, the company delivers integrated, customizable premium CRO services to global clients.

With this new chapter, Caremo is poised to write even more remarkable achievements in the pharmaceutical industry.

 

· About Caremo

Nanjing Caremo Biomedical Co., Ltd., founded in June 2020 by Dr. Zhang Xiaoqing—a National “Ten Thousand Talents Plan” expert and former founder of Huawe Medicine—is headquartered in Nanjing. The company provides global biotech and pharmaceutical enterprises with integrated, customizable R&D solutions, covering:

- Preclinical research

- CMC development

- Clinical trials

- Customized development

- New drug incubation and investment

- Capabilities and Infrastructure

 

Caremo’s end-to-end solutions and full-cycle project management accelerate drug development from concept to commercialization. The company employs a 500+ member R&D team with deep expertise in preclinical research and CMC, supported by 13,000+ sqm of chemistry and P2 laboratories compliant with China-U.S. regulatory standards, and hundreds of advanced instruments. A 35,000 sqm GLP-compliant R&D Headquarters is under construction.

To date, Caremo’s achievements include:

- High-Tech Enterprise

- Technology-based SME

- Jiangsu Provincial Private Technology Enterprise

- 2023 Jiangsu Potential Unicorn Enterprise

- Nanjing Municipal Special Dosage Form Drug Engineering Technology Research Center

- 2023 Most Competitive Pharmaceutical Service Enterprise in China

- 2022-2023 Top 50 Chinese Pharmaceutical R&D Enterprises

- 2023 Top 20 Chinese R&D CRO Enterprises

- 2022 Best Preclinical CRO/CDMO Enterprise (Emerging)

- Pharmaceutical Industry Law-abiding and Integrity Enterprise

- ISO 9001 Quality Management System Certification

Leveraging its platforms, Caremo will collaborate with global partners across the entire R&D value chain—from target validation to commercialization—through flexible models that address diverse client needs. The company aims to build a comprehensive, end-to-end drug discovery and production service platform, delivering full-spectrum technological and industrial support to empower global biopharmaceutical innovation.